Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Sarcoma 1Classical hematology 1

Conditions

Venous Thromboembolism 16Venous Thrombosis 10Pulmonary Embolism 9Neoplasms 7Thrombosis 2Thrombocytopenia 1Pancreatic Neoplasms 1Obesity 1Neoplasm Metastasis 1Mesenteric Ischemia 1Lung Neoplasms 1Intracranial Thrombosis 1Glioma 1Gastrointestinal Neoplasms 1Brain Neoplasms 1

Interventions

Tretinoin 2Gemcitabine 2venetoclax 1trametinib 1talazoparib 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1olaparib 1neratinib 1lorlatinib 1lenvatinib 1isoquercitrin 1idelalisib 1ferric carboxymaltose 1enzalutamide 1entrectinib 1enasidenib 1durvalumab 1dehydroftorafur 1darolutamide 1dacomitinib 1dabrafenib 1copanlisib 1cobimetinib 1cabozantinib 1cabazitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Dalteparin × Classical hematology × Clear all
NCT00966277 2016-12-12

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

M.D. Anderson Cancer Center

Phase 4 Completed
87 enrolled 9 charts
Classical hematologyGastrointestinal

Pancreatic Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡